Karo to acquire Novalon

Karo Bio (Stockholm, Sweden), which is developing nuclear receptor-targeted therapeutics using structure-based drug design, will acquire Novalon (Durham, N.C.) in a stock transaction. Novalon is developing BioKeys, small proteins that bind to protein targets such as nuclear receptors, for pharmaceutical screening and target validation. Novalon shareholders will own 20 percent of the combined company. ...